ACS-Biotech

ACS Biotech is a private, clinical-stage biotech firm developing a novel, cell-based cartilage gel for the repair of articular cartilage defects. Its core technology is a patented, physically crosslinked 3D chitosan hydrogel matrix that serves as a biomimetic scaffold for chondrocytes. The company is preparing for clinical trials for its lead product while generating early revenue through its research products and biobanking services. Based in Lyon, France, it leverages a team and scientific board with deep expertise in biomaterials, cartilage biology, and orthopaedic surgery.

Patented, physically crosslinked 3D chitosan hydrogel matrix. A biocompatible, biodegradable scaffold for cell support and tissue regeneration, usable in various forms (membrane, viscous gel, particles).

ACS Biotech competes in the cartilage repair and orthobiologics space against other cell-based therapies (e.g., MACI), scaffold technologies, and bone marrow stimulation techniques. Its key differentiator is its patented, physically crosslinked chitosan hydrogel, which it promotes as a superior biomimetic environment for chondrocytes. Broader competition includes large medical device companies and biotechs focused on osteoarthritis disease modification.